The Role of Biomarkers in Understanding oGVHD
oGVHD remains difficult to diagnose, stage, and monitor. Biomarkers may help move the field toward greater precision.
A biomarker is a measurable biological signal that provides information about disease activity, risk, progression, or treatment response. In oGVHD, researchers have studied molecular signals in tears, cytokines, proteomic markers, lipid mediators, leukocyte-related markers, genetic and molecular signatures, and imaging-based indicators.
The promise of biomarkers is not simply that they add more data. It is that they may help answer questions that clinical examination alone cannot fully resolve. Is the disease actively inflammatory? Is tissue damage progressing? Is the ocular surface at higher risk of complications? Is a therapy changing the underlying biology or mainly improving symptoms?
Tear fluid is a particularly important area of study because it can reflect the ocular surface environment. The tear film may contain inflammatory mediators and other molecular signals associated with immune activity. However, tear biomarker research is technically challenging. Tear volume may be low in oGVHD. Collection methods vary. Results can be affected by medications, disease severity, environment, and timing.
Imaging biomarkers may also be useful. Technologies that assess meibomian glands, corneal nerves, epithelial integrity, or ocular surface structure may provide information that symptoms alone cannot. These tools may help researchers understand which tissues are involved and how disease changes over time.
A 2024 systematic review of molecular biomarkers in oGVHD identified studies exploring cytokines, proteomics, genomics, immune response, imaging techniques, and dry-eye-related markers. The review also shows why the field is still developing. Biomarkers must be reproducible, clinically meaningful, and practical before they can be used widely.
For patients and advocates, biomarkers matter because they could support earlier recognition and more individualized care. If clinicians can identify disease activity before severe damage occurs, patients may have a better chance of preserving ocular function.
For clinical trials, biomarkers may help distinguish surface symptom relief from disease modification. That distinction matters in oGVHD, where the field needs therapies that address the underlying immune-mediated biology and not only transient discomfort.
Biomarkers will not replace patient-reported symptoms or clinical examination. The patient’s experience remains essential. But biomarkers may add a missing layer of biological evidence.
In oGVHD research, biomarkers represent the shift from describing what the disease looks like to measuring what the disease is doing.
This article is for educational purposes only and is not medical advice.
Sources:
- Micera A, et al. “Molecular Biomarkers in Ocular Graft-versus-Host Disease: A Systematic Review.” Biomolecules, 2024.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10813443/ - “Biomarkers in Ocular Graft-Versus-Host Disease: Implications for the Treatment of Ocular Surface Disease.” Transplantation and Cellular Therapy, 2022.
https://www.astctjournal.org/article/S2666-6367(22)01512-3/fulltext - Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/
